Global X Funds Global X 1-3 Month T-Bill ETF (ARCA: CLIP)

Dernières nouvelles pour Global X Funds Global X 1-3 Month T-Bill ETF (ARCA:CLIP)

The Fund invests at least 80 percent of its total assets, plus borrowings for investment purposes (if any), in the securities of the Solactive 1-3 month US T-Bill Index (the Underlying Index), and in securities that the Adviser determines have economic characteristics that are substantially identical to the economic characteristics of the securities that comprise the Underlying Index. In addition, in seeking to track the Underlying Index, the Fund may invest in debt securities that are not included in the Underlying Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds. The Fund's 80 percent investment policy is non-fundamental and requires 60 days prior written notice to shareholders before it can be changed.

Global X 1-3 Month T-Bill ETF

Global X Funds Global X 1-3 Month T-Bill ETF

Clip Money Inc

Clipper Realty Inc

WIIM

Intelligent Protection Management shares are trading higher after the company reported better-than-expected Q1 EPS results.

Verde Clean Fuels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VGAS#NASDAQ">VGAS</a>) reported quarterly losses of $(0.08) per share. This is a 38.46 percent increase over losses of $(0.13) per share from the same period last year.

Earnings

News

VGAS

Verde Clean Fuels Q1 EPS $(0.08) Up From $(0.13) YoY

Biomea Fusion, Inc. ("Biomea") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>), a clinical-stage diabetes and obesity medicines company, today announced that preliminary clinical data from the Phase I COVALENT-103 trial of BMF-500 in adults with acute leukemia (AL) were selected for a poster presentation at the European Hematology Association (EHA) 2025 Congress, taking place June 12–15 in Milan, Italy.
The presentation will highlight emerging safety, pharmacokinetics/pharmacodynamics (PK/PD), and clinical activity of BMF-500, a covalent FLT3 inhibitor, in patients with relapsed or refractory (R/R) AL, including those with FLT3 mutations (FLT3m) who have previously received FLT3 inhibitors such as gilteritinib (gilt).

Biotech

General

BMEA

Biomea Fusion's BMF-500 Selected For Poster Presentation At EHA 2025 Highlighting Phase I Data In Relapsed/Refractory Acute Leukemia

Management

AVNT

Avient Board of Directors Appoints Ashish K. Khandpur As Chairman Effective May 14

Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) reported quarterly earnings of $2.74 per share which beat the analyst consensus estimate of $2.59 by 5.79 percent. This is a 13.69 percent increase over earnings of $2.41 per share from the same period last year. The company reported quarterly sales of $1.48 billion which beat the analyst consensus estimate of $1.47 billion by 0.81 percent. This is a 4.37 percent increase over sales of $1.42 billion the same period last year.

Earnings Beats

Steris Q4 Adj. EPS $2.74 Beats $2.59 Estimate, Sales $1.48B Beat $1.47B Estimate

Dividends

Independence Realty Trust Increases Quarterly Dividend From $0.16 To $0.17

Most women in labor probably don't want their partner to leave them for a <a href="https://www.benzinga.com/personal-finance/25/05/45336434/billionaire-bill-gates-has-a-mcgold-card-that-gives-him-free-mcdonalds-meals-for-life-anywhere-in-the-world-but-says-i-tend-not-to-use-it">conference room and a cheeseburger</a>. But Melinda French Gates? She had a book. And apparently, a high tolerance for both contractions and Microsoft boardrooms.
In her <a href="https://www.facebook.com/share/r/16J2MP4K3u/?mibextid=wwXIfr">new memoir, "The Next Day",</a> French Gates shares a moment from the day her first child, Jennifer, was born—a moment that had the potential to spark social media fury if she hadn't beat everyone to the punchline.
"On the morning of April 26, 1999," she writes, "my water broke." She and Bill made their way to the hospital, only to be told she wasn't quite ready. Doctors even considered sending them home. What followed was a compromise worthy of a marriage negotiation handbook:
Don't Miss:
<ul class="wp-block-list">
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
"Ultimately, we settled on a compromise. I stayed at the hospital. Bill went to the office," she writes. And then, already anticipating the collective eye-roll, she added: "Before you roll your eyes, keep in mind that there really wasn't anything for him to do yet. Plus I had a good book with me."
What could've read as neglectful instead comes off as pragmatic—especially the way Melinda tells it. "In the end, I spent most of that magical day cheerfully alone," she notes, offering zero resentment and plenty of perspective.
But when active labor kicked in, so did the real discomfort—and Bill made it back in time for the action. That's when the cheeseburger incident happened. Melinda recalls asking her husband to remove his sweater "because it smelled like the hamburger he'd eaten on the way, and I was far too nauseated to deal with that."
Her labor lasted more than 14 hours, and at one point, in an effort to avoid a C-section, the doctor attempted a vacuum-assisted delivery. The attempt was brief—and loud. "The doctor [was] shrieking, ‘Turn it off!'" Melinda writes.
Trending: The team behind $6B+ in licensing deals is now building the next billion-dollar IP empire — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">invest early at $2.25/share.</a>
<a href="https://www.benzinga.com/real-estate/25/04/44891233/bill-gates-bought-his-daughter-a-16-million-horse-farm-as-a-graduation-gift-but-ex-wife-melinda-says">Jennifer was finally born</a> at 6:11 p.m., and Melinda describes being "absolutely smitten." It was a transformative moment that marked the beginning of her journey into motherhood in her early 30s—one she now reflects on with clarity, humor, and blunt honesty.
That story—and many others like it—takes on new weight knowing that <a href="https://www.benzinga.com/news/24/09/40852306/melinda-french-gates-embraces-independence-post-divorce-from-bill-gates-it-feels-quite-good">Melinda and Bill finalized their divorce in 2021</a> after nearly three decades of marriage.&nbsp;
She writes that she never expected to become a grandmother before turning 60, but in February 2023, she welcomed granddaughter Leila, followed by Mia just six months later. And just like the day she labored mostly solo while Bill went to work, she's handled this new chapter with grace and a little grit.
"There's a lot that's happened in my life over the last few years that I didn't see coming," she writes in "The Next Day," which was released last month. "During this season, I've seen my life change in ways I hoped for, ways I fought against, and ways I never could have imagined."
It's not the story of a tech titan's wife sitting at home—it's the story of a woman who made space for her own identity, one chapter at a time. And on that first chapter? A good book, some quiet time, and one very unwanted burger-scented sweater.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
Image: Shutterstock

Personal Finance

Melinda French Gates Says Bill Went To Work While She Was In Labor With First Baby —'Before You Roll Your Eyes, There Was Nothing For Him To Do Yet'

DXC Technology shares are trading lower after the company reported Q4 financial results and issued Q1 guidance below estimates. Also, the company issued FY26 adjusted EPS guidanc below estimates.

ISSC

Innovative Solns Q2 EPS $0.30 Beats $0.12 Estimate, Sales $21.90M Beat $14.23M Estimate

Earnings Misses

CSWC

Capital Southwest Q4 EPS $0.61 Misses $0.62 Estimate, Sales $52.40M Miss $52.71M Estimate

Logistic Properties (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LPA#AMEX">LPA</a>) reported $11.84 million in sales this quarter. This is a 12.94 percent increase over sales of $10.48 million the same period last year.

Logistic Properties Q1 Sales $11.84M Up From $10.48M YoY

Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.87) by 25.29 percent. This is a 32.93 percent decrease over losses of $(0.82) per share from the same period last year.

Kodiak Sciences Q1 EPS $(1.09) Misses $(0.87) Estimate

The Hartford Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) has outperformed the market over the past 5 years by 14.71% on an annualized basis producing an average annual return of 29.72%. Currently, The Hartford Insurance Gr has a market capitalization of $35.84 billion. 
Buying $100 In HIG: If an investor had bought $100 of HIG stock 5 years ago, it would be worth $357.84 today based on a price of $126.14 for HIG at the time of writing.
<h3>The Hartford Insurance Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747254612_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

A portion of the proceeds will be used by the joint venture to repay the $123.6 million mortgage loan encumbering the property.

Asset Sales

Vornado 55% Owned JV To Office Building For $205M

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 58.05% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed up 13.21% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 9.66% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 7.78% at $0.25</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Properties</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed up 7.68% at $0.42</li>
<li><a href="https://www.benzinga.com/quote/BLOZF">Cannabix Technologies</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLOZF#OTC">BLOZF</a>) shares closed up 6.62% at $0.45</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed up 6.45% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed up 5.68% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed up 4.17% at $1.00</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/FLOOF">Flower One Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FLOOF#OTC">FLOOF</a>) shares closed down 99.00% at $1e-06</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 20.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 20.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 13.50% at $1.00</li>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed down 8.33% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 7.90% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 6.54% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 5.70% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed down 4.76% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/ESE">ESCO Technologies</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESE#NYSE">ESE</a>) shares closed down 3.74% at $178.47</li>
<li><a href="https://www.benzinga.com/quote/CPHRF">Cipher Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CPHRF#OTC">CPHRF</a>) shares closed down 3.67% at $8.93</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 3.63% at $0.39</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed down 3.45% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 3.45% at $1.41</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 3.10% at $0.15</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

Movers

BBRRF

BLOZF

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CNBX

CNTMF

CPHRF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CVSI

CWBHF

CXXIF

ELLXF

FLOOF

FUAPF

GNLN

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

NWVCF

RMHB

SOLCF

TGIFF

UGRO

ZDPY

Marijuana Stock Movers For May 14, 2025

Boston Omaha (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOC#NYSE">BOC</a>) reported quarterly losses of $(0.02) per share. This is a 77.78 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $27.73 million which beat the analyst consensus estimate of $27.10 million by 2.32 percent. This is a 8.52 percent increase over sales of $25.55 million the same period last year.

Boston Omaha Q1 EPS $(0.02) Up From $(0.09) YoY, Sales $27.73M Beat $27.10M Estimate

Precigen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.08) by 125 percent. This is a 80 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $1.34 million which beat the analyst consensus estimate of $500.00 thousand by 168.20 percent. This is a 25.92 percent increase over sales of $1.06 million the same period last year.

PGEN

Precigen Q1 EPS $(0.18) Misses $(0.08) Estimate, Sales $1.34M Beat $500.00K Estimate

Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) reported $17.39 million in sales this quarter.

ALMS

Alumis Q1 Sales $17.39M

Graphjet Technology shares are trading higher after the company disclosed in 13D filing that its Co-Founder, CEO and CFO Aiden Lee Ping Wei reported A 48.9% stake in the company.

Acrivon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRV#NASDAQ">ACRV</a>) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.66) by 22.73 percent. This is a 30.14 percent increase over losses of $(0.73) per share from the same period last year.

Comments

Global X Funds Global X 1-3 Month T-Bill ETF

Actualités

Dernières nouvelles pour Global X Funds Global X 1-3 Month T-Bill ETF (ARCA:CLIP)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL